Novel strategies to promote resolution of inflammation to treat lower extremity artery disease.

Qian Zhang, Fengyang Li, Rebecca H Ritchie, Owen L Woodman, Xiaojun Zhou, Cheng Xue Qin

Current opinion in pharmacology 2022 Aug

filter terms:

Lower extremity artery disease (LEAD) is a chronic inflammatory disease that occurs when atherosclerotic plaques form in the lower extremities, which may lead to amputation if not manged properly. Given clinical standardcare (pharmacological and surgical) have limited efficacy in LEAD, developing novel strategies to manage LEAD remains an unmet clinical need. Given that active resolution of inflammation is essential to facilitate tissue healing and repair, failure to resolve inflammation may lead to chronic inflammation, dysregulated cellular homeostasis and adverse tissue remodeling. Several studies have demonstrated the importance of the balance between endogenous pro-resolving mediators and pro-inflammatory factors. There is growing evidence to suggest endogenous pro-resolving mediators engage with pro-resolving G-protein-coupled receptors to reduce the initiation and progression of inflammatory responses and to increase therapeutic angiogenesis in LEAD. Here, we highlight the mechanisms and the consequences of resolved inflammation, and the therapeutic potential of endogenous pro-resolving mediators-based strategy for this devastating disease. Copyright © 2022 Elsevier Ltd. All rights reserved.

Citation

Qian Zhang, Fengyang Li, Rebecca H Ritchie, Owen L Woodman, Xiaojun Zhou, Cheng Xue Qin. Novel strategies to promote resolution of inflammation to treat lower extremity artery disease. Current opinion in pharmacology. 2022 Aug;65:102263